RAPT Therapeutics (NASDAQ:RAPT) Given Neutral Rating at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT) in a report issued on Monday morning,Benzinga reports. HC Wainwright also issued estimates for RAPT Therapeutics’ Q4 2024 earnings at ($0.58) EPS, FY2024 earnings at ($2.56) EPS, Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.63) EPS and FY2025 earnings at ($2.61) EPS.

RAPT has been the subject of several other research reports. Stifel Nicolaus reiterated a “hold” rating and issued a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Wells Fargo & Company decreased their price objective on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. UBS Group dropped their target price on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a report on Monday, September 9th. JPMorgan Chase & Co. lowered shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday, November 11th. Finally, Piper Sandler cut shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $8.00 to $2.00 in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, RAPT Therapeutics currently has a consensus rating of “Hold” and an average price target of $9.50.

RAPT Therapeutics Price Performance

NASDAQ RAPT opened at $1.23 on Monday. The company has a market capitalization of $43.00 million, a price-to-earnings ratio of -0.44 and a beta of 0.33. RAPT Therapeutics has a 12 month low of $1.00 and a 12 month high of $27.35. The company’s fifty day moving average price is $1.79 and its two-hundred day moving average price is $2.60.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.09. As a group, analysts anticipate that RAPT Therapeutics will post -2.73 EPS for the current year.

Institutional Trading of RAPT Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in RAPT. Point72 Asset Management L.P. increased its stake in shares of RAPT Therapeutics by 176,725.0% during the second quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock valued at $2,157,000 after acquiring an additional 706,900 shares during the period. Federated Hermes Inc. raised its stake in shares of RAPT Therapeutics by 188.7% in the 2nd quarter. Federated Hermes Inc. now owns 796,080 shares of the company’s stock worth $2,428,000 after buying an additional 520,368 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of RAPT Therapeutics by 4,183.3% in the second quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock valued at $1,424,000 after buying an additional 456,275 shares during the period. Vanguard Group Inc. boosted its stake in RAPT Therapeutics by 21.2% during the first quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company’s stock valued at $22,386,000 after buying an additional 436,629 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its holdings in RAPT Therapeutics by 826.4% during the second quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company’s stock worth $900,000 after acquiring an additional 263,372 shares during the period. 99.09% of the stock is currently owned by institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.